Free Trial

Finch Therapeutics Group (FNCH) Competitors

Finch Therapeutics Group logo
$13.00 -0.08 (-0.57%)
As of 07/7/2025 11:45 AM Eastern

FNCH vs. CHRS, CLLS, CRBP, CLYM, ZNTL, JSPR, EXOZ, TCRX, ELUT, and VNRX

Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Coherus Oncology (CHRS), Cellectis (CLLS), Corbus Pharmaceuticals (CRBP), Climb Bio (CLYM), Zentalis Pharmaceuticals (ZNTL), Jasper Therapeutics (JSPR), eXoZymes (EXOZ), TScan Therapeutics (TCRX), Elutia (ELUT), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry.

Finch Therapeutics Group vs. Its Competitors

Finch Therapeutics Group (NASDAQ:FNCH) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 8.1% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Coherus Oncology has a consensus price target of $4.68, indicating a potential upside of 439.43%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Finch Therapeutics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Coherus Oncology
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Finch Therapeutics Group and Finch Therapeutics Group both had 1 articles in the media. Finch Therapeutics Group's average media sentiment score of 1.14 beat Coherus Oncology's score of 0.00 indicating that Finch Therapeutics Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Finch Therapeutics Group
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Coherus Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Finch Therapeutics Group has a net margin of 0.00% compared to Coherus Oncology's net margin of -66.30%. Coherus Oncology's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Coherus Oncology -66.30%N/A -26.51%

Coherus Oncology has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.47
Coherus Oncology$266.96M0.38$28.51M-$1.13-0.77

Finch Therapeutics Group has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Summary

Coherus Oncology beats Finch Therapeutics Group on 10 of the 14 factors compared between the two stocks.

Get Finch Therapeutics Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FNCH vs. The Competition

MetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$20.88M$210.39M$5.51B$8.96B
Dividend YieldN/AN/A5.25%4.02%
P/E Ratio-1.47N/A28.0520.15
Price / SalesN/A260.91438.14127.85
Price / CashN/A22.4437.0657.97
Price / Book0.915.908.125.62
Net Income-$74.75M-$96.61M$3.16B$248.50M
7 Day Performance-1.52%11.91%4.40%5.54%
1 Month Performance-2.89%6.54%4.09%7.52%
1 Year Performance870.15%10.85%34.53%22.06%

Finch Therapeutics Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FNCH
Finch Therapeutics Group
1.0587 of 5 stars
$13.00
-0.6%
N/A+870.1%$20.88MN/A-1.47190
CHRS
Coherus Oncology
3.7218 of 5 stars
$0.76
+4.0%
$4.68
+516.0%
-36.0%$84.78M$266.96M-0.67330
CLLS
Cellectis
2.8727 of 5 stars
$1.55
+1.6%
$4.00
+158.1%
-20.3%$84.76M$49.22M-1.80290
CRBP
Corbus Pharmaceuticals
3.8204 of 5 stars
$7.16
+3.8%
$50.88
+610.5%
-85.2%$84.43MN/A-1.7040
CLYM
Climb Bio
2.6274 of 5 stars
$1.19
-4.0%
$9.00
+656.3%
N/A$83.79MN/A-0.509Positive News
ZNTL
Zentalis Pharmaceuticals
1.5524 of 5 stars
$1.19
+2.6%
$8.37
+603.1%
-69.6%$83.46M$67.43M-0.38160
JSPR
Jasper Therapeutics
3.3331 of 5 stars
$5.74
+3.4%
$59.25
+932.2%
-85.7%$83.37MN/A-1.1020Trending News
Analyst Forecast
Analyst Revision
Gap Down
EXOZ
eXoZymes
N/A$9.75
-1.3%
N/AN/A$82.67M$70K0.0029Positive News
TCRX
TScan Therapeutics
2.5729 of 5 stars
$1.43
-1.4%
$7.80
+445.5%
-70.8%$82.06M$2.82M-1.31100News Coverage
ELUT
Elutia
3.1449 of 5 stars
$2.13
+7.6%
$8.00
+275.6%
-53.0%$81.41M$24.38M-1.10180
VNRX
VolitionRx
2.2683 of 5 stars
$0.77
+1.0%
$3.50
+355.8%
+15.3%$79.11M$1.31M-2.1380News Coverage
Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:FNCH) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners